Full Text View
Tabular View
No Study Results Posted
Related Studies
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
This study has been completed.
Study NCT00077688   Information provided by OncoGenex Pharmaceuticals
First Received: February 10, 2004   Last Updated: June 2, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bladder Neoplasms
Ureteral Neoplasms
Urethral Neoplasms
Carcinoma, Transitional Cell
Additional conditions recognized in this trial
Carcinoma
Neoplasms
Urinary Bladder Neoplasms
More general conditions related to this trial
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ureteral Diseases
Urethral Diseases
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
TOCOSOL Paclitaxel
Additional drug interventions recognized in this trial
Paclitaxel
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
OncoGenex Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services